The International Linked Clinical Trials (iLCT) programme is the flagship drug repurposing initiative of Cure Parkinson’s and Van Andel Institute (VAI) focussed on identifying and clinically testing already available drugs that show potential to slow, stop or reverse the progression of Parkinson’s.

Every year the iLCT committee of over 20 Parkinson’s specialists meet to discuss the progress of current iLCT clinical trials and importantly, debate a set of newly collated dossiers outlining current medical knowledge on a range of novel treatments which show potential for Parkinson’s. The iLCT committee then prioritise which of these treatments show the most promise for clinical testing; once a drug is prioritised, Cure Parkinson’s is mandated to take it into clinical trials. 

The pandemic has meant that the recent iLCT meetings have been virtual, however this has not diminished the determination and enthusiasm of the committee members to progress their objectives. This year the committee will meet to discuss the new drug dossiers in early October.

Here, Dr Simon Stott presents his 2021 update on current iLCT trials and those about to begin.

How helpful was this content?

/ 5. Vote count: